key: cord-0721983-kfxol11r
authors: Herishanu, Yair; Avivi, Irit; Levi, Shai; Shefer, Gabi; Bronstein, Yotam; Moshiashvili, Miguel Morales; Ziv, Tomer; Scarfò, Lydia; Perry, Chava; Ghia, Paolo
title: Six Months Antibody Persistence after BNT162b2 mRNA COVID-19 Vaccination in Patients with Chronic Lymphocytic Leukemia
date: 2021-10-09
journal: Blood Adv
DOI: 10.1182/bloodadvances.2021005998
sha: bfcc6e3b0af0cb9795b32e187962e56f1aae2411
doc_id: 721983
cord_uid: kfxol11r

nan

Coronavirus Disease 2019 (COVID-19) as well as mortality 1, 2 . We and others have reported that patients with CLL/small lymphocytic lymphoma (SLL) have an impaired antibody response to COVID-19 vaccination 3, 4 . Understanding the long-term persistence of SARS-CoV-2 antibodies after vaccination is highly important to ensure an appropriate vaccination strategy. COVID-19 mRNA-based vaccination in healthy subjects has been reported to elicit antibody response that persists for at least 6 months after the second vaccine dose 5 , however, the durability of humoral response in patients with CLL/SLL is still unknown. Here, we report an updated analysis of our primary cohort that now focuses on antibody persistence after a two-dose regimen of BNT162b2 COVID-19 vaccine in patients with CLL/SLL. This prospective study was conducted in the framework of the European Research Initiative on CLL (ERIC). The study was approved by the institutional review board and is registered in ClinicalTrials.gov, number NCT04746092 and all subjected provided informed consent.

Eligibility criteria for the study included diagnosis of CLL/SLL according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria 6 , age 18 years or older, with no known history of SARS-CoV-2 infection. The study has also included healthy volunteers that served as a control group. Patients and healthy controls who participated in the primary cohort and achieved a serologic response, 2-3 weeks after the second vaccine dose, were re-evaluated for antibody persistence at 6 months after vaccination. Serum samples were analyzed by the Elecsys® Anti-SARS-CoV-2S assay (Roche Diagnostics, Supplementary   1 ). For statistics see Supplementary 2 The primary cohort included a total 167 patients with CLL/SLL and 52 healthy subjects. As previously reported 3 , 66 of 167 patients (39.5%) and all 52 healthy controls obtained a serologic response, when measured at 2-3 weeks after the second vaccine dose. Among the responders, 61 patients with CLL/SLL and 39 healthy controls were evaluable for SARS-CoV-2s antibody testing 6 months after the second vaccine dose (patient baseline demographics and disease characteristics are summarized in Table 1 ). The median time from the second vaccine dose to the second serology test was 171.0 days (IQR, 168.0 -

Six months after the second vaccine dose, serum SARS-CoV-2s antibodies were still detectable in 90.2% (n=55) of the patients with CLL compared to 100% (n=39) of the controls (adjusted odds ratio=0.11, 95% CI 0.11-1.98; p=0.079; Figure 1A , Supplementary Table 1 ). The seropositivity rate was lowest in patients on active treatment, and significantly inferior compared to treatment naïve and previously treated patients (p=0.002; Figure 1B Patients who lost their initial humoral response were those who already had very low antibody levels when measured 2-3 weeks after the second vaccine dose [median 1.4 U/mL (IQR 1.2-2.2)]. Antibody level kinetics disclosed an overtime decline in antibody titers in most patient subgroups, which was much more pronounced in those with a strong initial immune response ( Figure 1F, Supplementary Table 4 ). During the 6 months follow-up of the primary cohort, symptomatic COVID-19 was diagnosed in only one seronegative patient and in none of the seropositive subjects.

In this report, we evaluated the persistence of SARS-CoV-2s antibodies after the second BNT162b2 mRNA COVID-19 vaccine dose. In both patients with CLL/SLL and healthy subjects, antibody titers declined significantly over time. However, in most patients and all controls, antibodies were still detectable at 6 months post vaccination. We found that at 6 months, antibody titers were lower in patients with CLL/SLL compared to the controls and low titers were particularly associated with active treatment. The six patients who became seronegative had a poor initial serologic response to the vaccine and most of them, either continued or initiated anti-CLL treatments during the post-vaccination period. We also show that in patients who had a robust initial antibody response after a second COVID-19 vaccine dose (patients that were altogether younger and with favorable CLL characteristics), the degree of antibody levels decay was more marked than in those with a weak initial response. It was recently reported 7 that among fully vaccinated health care workers, the occurrence of breakthrough infections with SARS-CoV-2 correlated with lower levels of both peri-infection neutralizing antibodies and anti-spike antibodies (compared to matched uninfected controls). Yet, the peak of the neutralizing and anti-spike antibodies within the first month after the second vaccine dose was more strongly associated with the risk of breakthrough infections 7 .

In summary, in the vast majority of patients with CLL who initially responded to a two-dose regimen of BNT162b2 COVID-19 vaccination, the antibody response was maintained at 6 months follow-up. However, antibody titers decreased significantly overtime and complete loss of response was associated with active treatment. Given that patients with CLL/SLL are at high risk for severe COVID-19 and SARS-CoV-2 antibodies levels reduce overtime, it may reasonable to consider administration of a another booster dose 6 months after the second vaccine dose.

For data sharing, contact the corresponding author: yairh@tlvmc.gov.il. 

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Seroconversion rates following COVID-19 vaccination among patients with cancer

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

The authors would like to thank the clinical study coordinators and nurses at the hematology department in the Tel-Aviv Sourasky medical centre.

YH and IA-Initiated the trial, designed the study analyzed data and wrote the paper. GS